<HashMap><database>GEO</database><file_versions><headers><Content-Type>application/xml</Content-Type></headers><body><files><Other>ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE306nnn/GSE306012/</Other></files><type>primary</type></body><statusCode>OK</statusCode><statusCodeValue>200</statusCodeValue></file_versions><scores/><additional><omics_type>Transcriptomics</omics_type><species>Mus musculus</species><gds_type>Expression profiling by high throughput sequencing</gds_type><full_dataset_link>https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE306012</full_dataset_link><repository>GEO</repository><entry_type>GSE</entry_type></additional><is_claimable>false</is_claimable><name>Temporal inhibition of ADAM17 in fibroblasts reduces stiffness and promotes vascularization following myocardial infarction</name><description>Myocardial infarction (MI) triggers a complex remodelling process that leads to heat failure if uncontrolled. A Disintegrin and metalloproteinase-17 (ADAM17), a transmembrane sheddase, is upregulated in patients with ischemic cardiomyopathy, colocalized to myofibroblasts (myoFB) in the infarct tissues. Fibroblasts are key players in post-MI scar formation and exist in different states with diverse functions. Using mice with inducible Adam17 deletion in homeostatic FBs (Adam17 FB-KD ), or activated FBs (Adam17 myoFB-KD ), we found that ADAM17 loss in homeostatic FBs impaired infarct formation post-MI and increased mortality due to left ventricular (LV) rupture. Conversely, ADAM17 loss in myoFBs limited infarct expansion, LV dilation and dysfunction up to 4 weeks post-MI. Ex vivo and in vitro experiments revealed that the beneficial effects in Adam17 myoFB-KD mice are due to reduced stiffness of the infarct tissue through suppressing activation of EGFR-YAP-pathway, which promoted vascularization and thereby limited infarct expansion. Pharmacological inhibition of ADAM17 prior to MI was ineffective, but short-term ADAM17 inhibition after MI by targeting myoFBs significantly alleviated the adverse LV remodeling and dysfunction with beneficial effects up to 4wks post-MI. Our study identifies a short-term therapeutic window for ADAM17 inhibition to prevent long-term adverse remodeling, dysfunction and heart failure post-MI.</description><dates><publication>2026/07/22</publication></dates><accession>GSE306012</accession><cross_references><GSM>GSM9191554</GSM><GSM>GSM9191576</GSM><GSM>GSM9191575</GSM><GSM>GSM9191553</GSM><GSM>GSM9191574</GSM><GSM>GSM9191552</GSM><GSM>GSM9191573</GSM><GSM>GSM9191558</GSM><GSM>GSM9191557</GSM><GSM>GSM9191579</GSM><GSM>GSM9191578</GSM><GSM>GSM9191577</GSM><GSM>GSM9191555</GSM><GSM>GSM9191583</GSM><GSM>GSM9191560</GSM><GSM>GSM9191582</GSM><GSM>GSM9191581</GSM><GSM>GSM9191580</GSM><GSM>GSM9191565</GSM><GSM>GSM9191563</GSM><GSM>GSM9191585</GSM><GSM>GSM9191584</GSM><GSM>GSM9191562</GSM><GSM>GSM9191568</GSM><GSM>GSM9191567</GSM><GSM>GSM9191572</GSM><GSM>GSM9191571</GSM><GSM>GSM9191570</GSM><GPL>30172</GPL><GSE>306012</GSE><taxon>Mus musculus</taxon><PMID>[41524432]</PMID></cross_references></HashMap>